B8299
N-Butyldeoxynojirimycin
film (dried in situ), ≥98% (TLC)
Synonym(s):
Miglustat, NB-DNJ
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H21NO4
CAS Number:
Molecular Weight:
219.28
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.32
MDL number:
Product Name
N-Butyldeoxynojirimycin, film (dried in situ)
SMILES string
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
InChI
1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
InChI key
UQRORFVVSGFNRO-UTINFBMNSA-N
assay
≥98% (TLC)
form
film (dried in situ)
solubility
water: 9.80-10.20 mg/mL, clear, colorless
storage temp.
2-8°C
Quality Level
Gene Information
human ... UGCG(7357)
Related Categories
Application
N-Butyldeoxynojirimycin has been used:
- in the inhibition of glycolipid synthesis in neuroblastoma cells
- in the inhibition the ceramide-specific glycosyltransferase in hepatocytes
- in the inhibition of β-glucosidase (GBA2) using fluorescence- activity assay in human embryonic kidney (HEK293) cells.
Biochem/physiol Actions
α-glucosidase Inhibitor
N-Butyldeoxynojirimycin is an inhibitor of glucosyltransferase and α-glucosidases. N-Butyldeoxynojirimycin, also known as misglustat, reduces glycolipid levels by substrate reduction therapy (SRT) and is effectively used for the treatment of glycosphingolipid lysosomal storage disorder, Gaucher disease.
General description
N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Andrés Felipe Leal et al.
International journal of molecular sciences, 21(17) (2020-09-02)
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff
Beom Hee Lee et al.
Medicine, 96(45), e8492-e8492 (2017-11-16)
Gaucher disease (GD) is caused by a deficiency in the lysosomal enzyme glucocerebrosidase. Enzyme replacement therapy (ERT) is recommended for clinical improvement. The efficacy and safety of a new imiglucerase, Abcertin, were assessed in 7 Egyptian patients with treatment-naïve type
How adhesion/growth-regulatory galectins-1 and-3 attain cell specificity: case study defining their target on neuroblastoma cells (SK-N-MC) and marked affinity regulation by affecting microdomain organization of the membrane
Kopitz J, et al.
IUBMB Life, 62(8), 624-628 (2010)
Imiglucerase in the treatment of Gaucher disease: a history and perspective
Deegan PB and Cox TM
Drug design, development and therapy, 6, 81-81 (2012)
Tobias Schwerd et al.
Gut, 66(6), 1060-1073 (2016-03-10)
Patients with Niemann-Pick disease type C1 (NPC1), a lysosomal lipid storage disorder that causes neurodegeneration and liver damage, can present with IBD, but neither the significance nor the functional mechanism of this association is clear. We studied bacterial handling and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service